HIV-associated wasting in the era of highly active antiretroviral therapy: a syndrome of residual HIV infection in monocytes and macrophages?

Clin Infect Dis. 2005 Jun 15;40(12):1846-8. doi: 10.1086/430376. Epub 2005 May 3.

Abstract

Human immunodeficiency virus (HIV) infection in peripheral blood mononuclear cells (PBMCs) might be influencing the development of wasting in the era of potent antiretroviral therapy. In a retrospective study of 57 subjects, HIV proviral DNA levels in PBMCs were higher in subjects whose body weight decreased by >5% one year after initiation of highly active antiretroviral therapy, compared with subjects whose body weight was stable or increased (median HIV proviral DNA load, 8.9 vs. 0.9 copies/10(6) PBMCs; P = .006).

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Antiretroviral Therapy, Highly Active*
  • Antiviral Agents / therapeutic use
  • Body Weight
  • CD4 Lymphocyte Count
  • Case-Control Studies
  • DNA, Viral
  • HIV Infections / complications*
  • HIV Infections / drug therapy
  • HIV Infections / virology*
  • HIV Wasting Syndrome / etiology*
  • HIV Wasting Syndrome / virology*
  • Humans
  • Middle Aged
  • Monocytes / virology*
  • Retrospective Studies
  • Viral Load

Substances

  • Antiviral Agents
  • DNA, Viral